行情

NBIX

NBIX

神经分泌生物科学
NASDAQ

实时行情|Nasdaq Last Sale

114.06
+1.05
+0.92%
交易中 13:42 08/12 EDT
开盘
113.14
昨收
113.01
最高
115.46
最低
113.01
成交量
30.62万
成交额
--
52周最高
136.27
52周最低
72.14
市值
106.36亿
市盈率(TTM)
54.16
分时
5日
1月
3月
1年
5年

分析师评级

24位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NBIX价格均价为140.29,最高价位161.00,最低价为120.00。

EPS

NBIX 新闻

更多
Neurocrine Biosciences Inc (NBIX) Q2 2020 Earnings Call Transcript
NBIX earnings call for the period ending June 30, 2020.
Motley Fool · 08/04 13:30
Credit Suisse Maintains Neutral on Neurocrine Biosciences, Lowers Price Target to $126
Credit Suisse analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Neutral and lowers the price target from $135 to $126.
Benzinga · 08/04 12:48
Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $146
Morgan Stanley maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $149 to $146.
Benzinga · 08/04 12:35
How Neurocrine Biosciences Crushed It in Q2
Neurocrine Biosciences' (NASDAQ: NBIX) 30% plunge earlier this year during the coronavirus-fueled market meltdown is practically all but forgotten now. Here's what you need to know about Neurocrine's impressive Q2 update. Neurocrine reported revenue of $302.
Motley Fool · 08/04 10:34
JP Morgan Downgrades Neurocrine Biosciences to Neutral, Announces $136 Price Target
JP Morgan analyst Anupam Rama downgrades Neurocrine Biosciences (NASDAQ:NBIX) from Overweight to Neutral and announces $136 price target.
Benzinga · 08/04 09:35
Neurocrine Bio beats Q2 views on strong Ingrezza sales
Neurocrine Biosciences (NASDAQ:NBIX) Q2 results: Revenues: $302.4M (+64.8%); Ingrezza sales: $267.6M (+48.2%). Net income: $79.6M (+55.2%); non-GAAP net in
seekingalpha · 08/04 02:02
Neurocrine Biosciences EPS beats by $0.40, beats on revenue
Neurocrine Biosciences (NASDAQ:NBIX): Q2 Non-GAAP EPS of $1.42 beats by $0.40; GAAP EPS of $0.81 beats by $0.15. Revenue of $302.4M (+64.7% Y/Y) beats by $
seekingalpha · 08/04 01:02
Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of 24.62% and 18.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/03 21:15

所属板块

生物技术和医学研究
+0.48%
制药与医学研究
+1.62%

热门股票

代码
价格
涨跌幅

NBIX 简况

Neurocrine Biosciences, Inc.主要开发治疗神经和内分泌疾病和病症的药物。该公司两个主导的晚期临床计划是Elagolix和NBI-98854(valbenazine)。Elagolix是一种与AbbVie Inc.(AbbVie)合作开发出有利于女性健康的促性腺激素释放激素(GnRH)拮抗剂。NBI-98854(valbenazine)是一种用于治疗运动障碍的水泡单胺转运蛋白2(VMAT2)抑制剂。该公司专注于开发治疗特发性震颤的NBI-640756。其研究和开发专注于解决中枢神经和内分泌系统的疾病和病症,包括从下丘脑-垂体-肾上腺(HPA)病症到压力相关病症和神经/神经精神疾病的治疗类别。其促肾上腺皮质激素释放因子(CRF)是一种直接释放到垂体门静脉血管系统的下丘脑激素。
展开

微牛提供Neurocrine Biosciences, Inc.(NASDAQ-NBIX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NBIX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NBIX股票基本功能。